Introduction
TYK Medicines Inc is a China-based company mainly engaged in developing and commercializing pharmaceutical products. The Company is primarily focused on small molecule drug development, and its main products include TY-9591, TY-302 and TY-2136. TY-9591 is a third-generation EGFR-TKI with antitumor effects on EGFR mutations. TY-302 is a potent, selective oral CDK4/6 inhibitor developed for the treatment of advanced solid tumors, including breast cancer and prostate cancer. TY-2136b is an internally developed, oral ROS1/NTRK inhibitor for the treatment of solid tumors.